Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BRG01 injection in EBV-positive recurrent or metastatic nasopharyngeal carcinoma
CTR20244732Phase 2Active
- Sponsor
- Biosyngen
- Start
- Dec 2024
- Modality
- Bone Marrow HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Peripheral Blood HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous anti-EBV CAR T cells BRG01 in nasopharyngeal carcinoma (NPC), sponsored by Biosyngen. Started Dec 2024; status: active.
02
Drugs
autologous anti-EBV CAR T cells BRG01
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20244732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244732.